Pharsight

Olysio patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7671032 JANSSEN PRODS HCV NS-3 serine protease inhibitors
May, 2025

(1 year, 7 months from now)

US9856265 JANSSEN PRODS Macrocyclic inhibitors of hepatitis C virus
Jul, 2026

(2 years from now)

US8349869 JANSSEN PRODS Macrocylic inhibitors of hepatitis C virus
Jul, 2026

(2 years from now)

US8741926 JANSSEN PRODS Macrocyclic inhibitors of hepatitis C virus
Jul, 2026

(2 years from now)

US9040562 JANSSEN PRODS Macrocyclic inhibitors of hepatitis C virus
Jul, 2026

(2 years from now)

US8754106 JANSSEN PRODS Macrocyclic inhibitors of hepatitis C virus
Jul, 2026

(2 years from now)

US8148399 JANSSEN PRODS Macrocyclic inhibitors of hepatitis C virus
Sep, 2029

(5 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9623022 JANSSEN PRODS Macrocyclic inhibitors of hepatitis C virus
Jul, 2026

(2 years from now)

US9353103 JANSSEN PRODS Macrocyclic inhibitors of hepatitis C virus
Jul, 2026

(2 years from now)

Olysio is owned by Janssen Prods.

Olysio contains Simeprevir Sodium.

Olysio has a total of 9 drug patents out of which 0 drug patents have expired.

Olysio was authorised for market use on 22 November, 2013.

Olysio is available in capsule;oral dosage forms.

Olysio can be used as method of treating hepatitis c.

The generics of Olysio are possible to be released after 05 September, 2029.

Drugs and Companies using SIMEPREVIR SODIUM ingredient

Market Authorisation Date: 22 November, 2013

Treatment: Method of treating hepatitis c

Dosage: CAPSULE;ORAL

More Information on Dosage

OLYSIO family patents

Family Patents

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic